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Abstract
Background: Cryptococcal meningitis (CM) constitutes a significant source of mortality in resource-limited regions.
Cryptococcal antigen (CRAG) can be detected in the blood before onset of meningitis. We sought to determine the
cost-effectiveness of implementing CRAG screening using the recently developed CRAG lateral flow assay in Uganda
compared to current practice without screening.
Methods: A decision-analytic model was constructed to compare two strategies for cryptococcal prevention among
people living with HIV with CD4 < 100 in Uganda: No cryptococcal screening vs. CRAG screening with WHO-
recommended preemptive treatment for CRAG-positive patients. The model was constructed to reflect primary
HIV clinics in Uganda, with a cohort of HIV-infected patients with CD4 < 100 cells/uL. Primary outcomes were
expected costs, DALYs, and incremental cost-effectiveness ratios (ICERs). We evaluated varying levels of programmatic
implementation in secondary analysis.
Results: CRAG screening was considered highly cost-effective and was associated with an ICER of $6.14 per
DALY averted compared to no screening (95% uncertainty range: $-20.32 to $36.47). Overall, implementation
of CRAG screening was projected to cost $1.52 more per person, and was projected to result in a 40% relative reduction
in cryptococcal-associated mortality. In probabilistic sensitivity analysis, CRAG screening was cost-effective in 100% of
scenarios and cost saving (ie cheaper and more effective than no screening) in 30% of scenarios. Secondary analysis
projected a total cost of $651,454 for 100% implementation of screening nationally, while averting 1228 deaths
compared to no screening.
Conclusion: CRAG screening for PLWH with low CD4 represents excellent value for money with the potential
to prevent cryptococcal morbidity and mortality in Uganda.
Background
Cryptococcal meningitis (CM) constitutes a significant
source of global morbidity and mortality for people living
with HIV (PLWH), particularly in resource limited set-
tings [1]. Nearly 1 million cases of cryptococcal disease
with 625,000 deaths are estimated to occur annually, sur-
passing tuberculosis and other opportunistic infections in
some highly prevalent areas [1]. Of these, the vast majority
of cases occur in sub-Saharan Africa, where CM is the
cause of 10–44% of HIV-associated deaths [1–4]. New
cost-effective approaches for prevention, detection and
treatment of cryptococcal disease are needed.
Several factors contribute to high cryptococcal morbid-
ity and mortality, including difficulty with accurate diag-
nosis and complicated disease management consisting of
hospitalization, serial lumbar punctures, and expensive
treatments that are difficult to access such as amphoteri-
cin and flucytosine, both with significant side effects [5, 6].
CM mortality remains high in both resourced (9–38%)
and resource-limited settings (30–59%) despite increasing
access to ART, likely due to late presentation [7, 8]. Uni-
versal primary prophylaxis (UPP) with fluconazole has not
demonstrated a clear mortality reduction and incurs sig-
nificant costs and side effects [7, 9, 10]. Strategies that
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allow targeted early interventions to identify those at
greatest risk for cryptococcal disease are thus warranted.
To this end, cryptococcal antigen (CRAG) screening of
immunosuppressed HIV-infected (CD4 < 100 cells/μL)
allows early identification of individuals with crypto-
coccal infection or those at risk for increased mortality.
In 2011, the cryptococcal antigen Lateral Flow Assay
(IMMY CrAg LFA, Norman, OK, 2011), was developed.
This is a rapid dipstick test, approved by the Food and
Drug Administration, with a very high sensitivity and
specificity for detecting cryptococcal glucuronylmannan
in serum [11–16]. CRAG LFA is heat-stable, inexpensive
(estimated $2.50 per test), and requires minimal training
for optimal use in resource-limited settings. Several
studies have demonstrated its effectiveness in detecting
cryptococcal antigenemia and diagnosing cryptococcal
disease [17, 18].
CRAG is detectable in the blood 3 weeks before onset
of meningitis, and is an independent predictor of menin-
gitis and death [19–23]. CRAG screening targeting those
HIV-infected with a CD4 count <100 cells/uL is now
recommended by the WHO, and several national HIV
guidelines [24]. For those who are CRAG positive, pre-
emptive treatment with fluconazole (800 mg for 2 weeks,
followed by 400 mg for 8 weeks) reduces mortality [25].
Despite the WHO recommendations, implementation
and scale-up of CRAG screening remains limited in
Sub-Saharan Africa. Fewer than 30% of eligible patients
receive screening, partly due to concerns regarding cost
and feasibility of incorporation into routine HIV care
[26]. Previous economic evaluations from middle-
income settings have suggested that incorporating
CRAG-LFA screening into HIV care may be cost-
effective at current willingness to pay thresholds [27].
There is a lack of data from low-income settings in Sub-
Saharan Africa where disease burden is highest [28–30].
Meya et al. previously assessed costs of CRAG screening
using a latex agglutination assay ($16 per test) in Uganda
as part of a cohort study; however, the cost-effectiveness
of population-level implementation was not evaluated
[28]. The impact of preemptive treatment, relapse, or
loss to follow-up on the cost-effectiveness of CRAG
screening has not been modeled, and an economic ana-
lysis of the impact and cost of scaling up current screening
protocols is important for guiding policy decisions. Fur-
thermore, alternative implementation algorithms includ-
ing intensified diagnostic evaluation of all CRAG-positive
patients or full CM treatment for all CRAG-positive pa-
tients may improve morbidity and mortality for patients
with sub-clinical CM disease. Current recommendations
do not have provisions for such intensified diagnostics,
and have not evaluated their cost-effectiveness.
We thus sought to evaluate the costs and cost-
effectiveness of implementing CRAG screening for
PLWH with advanced immunosuppression (including
preemptive treatment for those CRAG positive) com-
pared to current practice in Uganda. Additionally, we
sought to explore the health-system costs of CRAG
screening at various levels of programmatic implementa-
tion as well as alternative algorithms for screening.
Methods
We conducted a cost-effectiveness analysis from a
health-systems perspective using a decision-analytic
model (Fig. 1) with a target population of HIV-infected,
ART-naïve Ugandan patients with a baseline CD4 < 100
cells/μL. We used a 1-year time-frame for the interven-
tion, and evaluated outcomes from cryptococcal disease
over a 5-year period. Disability-adjusted life years
(DALYs) were analyzed across a lifetime horizon of the
cohort representing PLWH on ART. The model was de-
veloped and analyzed using TreeAge software (TreeAge
Software Inc., Williamstown, MA, USA).
Decision-Tree Model
Two practices for PLWH with CD4 < 100 cells/uL were
compared: No screening vs universal CRAG screening
followed by preemptive treatment for those CRAG positive.
In both model arms, patients were stratified by preva-
lence of baseline CM disease and cryptococcal antigene-
mia, based on currently available data from published
literature [20, 25, 28, 29] (Table 1). All patients in both
model arms were initiated on ART per current guide-
lines in Uganda. Regardless of CRAG screening strategy,
all patients with symptoms concerning for CM at pres-
entation (eg. headache, fever, or neck stiffness) were as-
sumed to receive a lumbar puncture (LP) and treatment
for baseline CM if diagnosed, consisting of Amphoteri-
cin B 0.7 mg/kg/day for 2 weeks, followed by Flucona-
zole 800 mg for 3 weeks and Fluconazole 400 for 9
weeks, with potential for future relapse [30]. All patients
without initial CM disease could progress to develop
CM, based on current literature estimates and adjusted
based on model interventions such as receiving preemp-
tive treatment. Given uncertainty in long-term pro-
gression rates, we focused on short/medium term
progression over 5 years [31]. Patients that progressed to
develop CM could either be detected and treated, or lost
to follow-up. Untreated CM among PLWH was assumed
to have 100% mortality [8]. Within each arm of the
model, PLWH that were successfully treated for CM dis-
ease could still go on to have disease relapse (Fig. 1).
In order to evaluate the impact and cost-effectiveness
of CRAG screening, rates of diagnosis and/or develop-
ment and treatment of CM differed between the model
arms based on usage of CRAG screening. In the ‘no
screening’ arm, no CRAG screening was performed and
no prophylactic antifungal therapy was administered.
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Asymptomatic patients were assumed to receive no fur-
ther immediate cryptococcal related care, while symp-
tomatic patients received evaluation as described above;
patients without baseline CM were considered at risk for
development of CM with rates dependent on prevalence
of (undetected) cryptococcal antigenemia.
In the CRAG screening intervention arm, patients re-
ceived a serum CRAG test using the LFA to identify
cryptococcal antigenemia. In the base case, symptomatic
CRAG-positive patients received further evaluation as de-
scribed above, while asymptomatic CRAG-positive pa-
tients received no further evaluation. All asymptomatic
CRAG-positive patients received preemptive treatment for
cryptococcal antigenemia (fluconazole 800 mg for 2 weeks
followed by 400 mg for 8 weeks) along with ART initiation
per current Ugandan guidelines [24, 30]. We incorporated
the protective effect of preemptive treatment as a reduc-
tion in the risk of developing CM, and as partial treatment
for those with subclinical baseline CM [25, 26, 29–33].
CRAG negative patients began ART without further test-
ing or treatment, and were at risk for development of CM
based on literature estimates (Table 1).
To aid in programmatic implementation, we conducted
secondary analysis to explore alternative interventions for
individuals with baseline CRAG positivity in the CRAG-
screening intervention arm, including an intensified case-
finding algorithm consisting of an LP for evaluation of CM
in all CRAG positive patients regardless of symptoms
(in base case analysis, only symptomatic patients receive
LP and asymptomatic patients receive preemptive ther-
apy). In this algorithm, CRAG positive patients diagnosed
with CM disease after LP receive full CM treatment, while
CRAG positive patients without a diagnosis of CM after
LP are treated with preemptive therapy. We additionally
explored provisions for full CM treatment to all CRAG
positive patients, without requiring LP or additional diag-
nostic workup. The effect of each of these clinical
algorithms on ICER values for CRAG-LFA screening was
determined. Policy makers must also consider the costs
and impact of scaling up new screening strategies. As such,
in additional secondary analysis, we also modeled the net
costs, effects, and cost-effectiveness of population level
scale-up of CRAG screening, by varying the percentage of
individuals (accessing HIV care in a given year) receiving
CRAG screening, and compared these to the current prac-
tice arm. The absolute number of Ugandans enrolling in
HIV care per year with CD4 < 100 was estimated to be
61,400 and was varied widely in sensitivity analysis [34].
Fig. 1 Model Schematic. Abbreviations: CRAG-LFA—cryptococcal antigen lateral flow assay, CM—cryptococcal meningitis, ART—antiretroviral
therapy. Decision-analytic model schematic. We modeled progression or relapse of CM over a 5 year time period for a cohort of PLWH with
CD4 < 100. In both model arms, symptomatic patients at baseline receive evaluation for CM assumed to include a lumbar puncture (LP), and
treatment if diagnosed with CM. We assumed ART initiation in all arms. The model compares two interventions for prevention of cryptococcal
morbidity for those without a baseline diagnosis of CM: 1) No screening, in which patients receive no CM screening or prophylaxis 2) CRAG-LFA, in
which all patients receive serum CRAG-LFA screening. Individuals with positive CRAG were assumed to receive the cryptococcal preemptive treatment
for cryptococcal antigenemia with fluconazole 800 mg for 2 weeks, followed by fluconazole 400 mg for 8 weeks. CRAG-negative individuals receive no
further antifungal therapy. a outlines the two main model arms. b demonstrates the diagnostic evaluation and treatment for suspected CM cases
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Epidemiologic, diagnostic, and treatment parameters
Key model parameters, values, and ranges are shown in
Table 1. Variables including prevalence of cryptococcal
antigenemia, percentage uptake, and percent of HIV pa-
tients with CD4 count <100 cells/μL were varied widely
in sensitivity analysis to incorporate findings from mul-
tiple countries. For variables with limited data, uncer-
tainty ranges were determined by varying base case
values by ±75%. Probabilistic sensitivity analysis using
Monte-Carlo simulation was conducted to simultan-
eously vary all parameters across their ranges to generate
95% uncertainty ranges (UR) for outcome estimates of
costs, DALYs and cost-effectiveness.
Costs
Costs were derived from literature estimates as well as
invoices from the Infectious Disease Institute in
Kampala, Uganda and are presented in 2016 US dollars.
Table 1 Key Parameter Estimates
Parameter name Value Range Source
Epidemiology
Number of patients enrolling in HIV care in Uganda
per year
245,600 150,000–350,000 [34]
Total number of patients enrolling in HIV care per year
with CD4 < 100 (% of total)
61,400 (25%) 13,000 (5%) -105,000 (30%) [34]
Average age of cohort 37 32–44 [41]
Life Expectancy in yearsa (on ART) 19.1 17–23 [41]
CRAG-positive prevalence (at baseline) 8.80% 1–20% [20, 29, 31, 32]
Percentage of CRAG+ patients with baseline CM disease 25% 0–50% [33, 45]
Proportion developing CM among CRAG positive patients
without treatmentb
34% 10–75% [21, 23, 31, 29]
Relative reduction in CM development among CRAG positive
patients on CPETb,c
65% 10–90% [51, 26, 29, 31]
Proportion developing CM among CRAG negative patientsb 0.8% 0–2% [10, 21, 29]
Treatment
Survival of diagnosed CM with full CM treatment 70% 50–90% [30]
Survival of CM without treatment 0%
Relapse rate for treated CMd 12.50% 9–16% [26, 43]
Disability Weights
CM disease 0.615 0.46–0.77 [52, 53]
HIV (on ART) 0.053 0.039–0.066 [52, 53]
CM treatment 0.05 0.0375–0.0625 [52, 53]
(Assumption)
Costs
CRAG-LFA $2.52 $1.50–$10.00 [38]
Lumbar Puncture $8.08 $6.03–$10.42 [35, 38]
CM Diagnosis (lab and staff costs) $7.07 $2.42–$12.79 [35–38]
Preemptive treatment: Fluconazole 800 mg daily for 2 weeks,
then 400 mg daily for 8 weeks
$22.22 $17.00–$33.00 [24, 35]
CM Treatment: Amphotericin B 0.7 mg/kg/day for 2 weeks,
then fluconazole 800 mg for 3 weeks and fluconazole 400 for
9 weeks
$343.28 $200–$600 [33–35]
Abbreviations: CRAG-LFA cryptococcal antigen lateral flow assay, CPET WHO Cryptococcal Pre-emptive therapy, CM cryptococcal meningitis, ART
antiretroviral therapy
aLife expectancy was estimated to be reduced by 25% in CRAG positive individuals, independent of development of CM, to account for higher observed mortality
in this population in recent cohort studies [20]
bCRAG-LFA testing was a component of only the CRAG-LFA screening intervention; However, risk of progression to CM for all model arms was stratified based on
epidemiologic data on prevalence of baseline CRAG positivity
cAbsolute and relative risk reduction were calculated based on available studies of fluconazole therapy in CRAG positive patients [26, 29, 31]. An estimated 15% of
patients in all model arms were considered lost to follow up over the time horizon of the model, with higher rates of CM development and relapse. Sensitivity
analysis was conducted around these parameters
dAssuming a 75% case detection rate for symptomatic CM disease
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Costs of the CRAG LFA, lumbar puncture, and CM
diagnosis were based on estimates accounting for
personnel, materials, and outpatient visit costs, and are
summarized in Table 1. Medication costs were based on
prices available in Uganda from the Joint Medical
Service [35–39]. Full CM treatment cost included the
price of medication (Amphotericin B and Fluconazole),
hospitalization, and therapeutic laboratory monitoring.
Lifetime costs of ART and HIV care were not included
in the base case analysis. However, to determine the im-
pact of ART costs on the cost-effectiveness of CRAG
screening, secondary analyses were performed to calcu-
late the ICER inclusive of lifetime ART cost. Costs for
future years were discounted at 3% [40–42].
Outcomes
The primary outcomes of the model were DALYs calcu-
lated based on disability attributable to CM disease with
associated treatments, and years of life lost from CM-
associated mortality (Table 1). We assumed near full life
expectancy for individuals without CM disease with
ART, based on site-specific data in Uganda for HIV-
infected persons [41].
Cost-effectiveness was represented by the incremental
cost-effectiveness ratio (ICER) comparing model arms,
and assessed relative to WHO’s suggested country-
specific willingness-to-pay (WTP) threshold, defined in
our analysis as per-capita Ugandan gross domestic prod-
uct (GDP $572) per DALY averted [43, 44].
Results
Costs
Projected costs are summarized in Table 2. The incremen-
tal health system cost of the CRAG screening intervention
in the base case scenario (i.e.100% implementation of
CRAG screening for 1 year; total costs inclusive of a 5 year
time period of downstream costs) was projected to be
$1.52 (95%UR: $-5.46 to $9.42) more than ‘no screening’
per patient,. The diagnostic costs of the CRAG-LFA test-
ing algorithm ($2.71 per person, inclusive of all diagnostic
workup costs) were largely offset by averted costs associ-
ated with reduced development and treatment of CM
when compared to costs of no screening (treatment costs
for CRAG-LFA arm: $7.90 per person, compared to $8.85
for no screening).
Effectiveness
CRAG screening, implemented for all eligible individ-
uals, resulted in improved health benefits compared to
no screening (25 DALYs averted per hundred individ-
uals), as summarized in Table 2. In the CRAG screening
intervention arm, use of preemptive therapy among
CRAG positive patients was projected to reduce CM de-
velopment and thus early CM mortality. We estimated
that implementation of CRAG screening resulted in a
relative risk reduction in cryptococcal-associated mortal-
ity of 44% compared to CP (Absolute CM mortality pro-
jections: No screening 45 deaths per 1000 PLWH,
CRAG screening 25 deaths per 1000 PLWH).
Cost-effectiveness
In the base case analysis, 100% implementation of CRAG
screening (with preemptive therapy for CRAG-positive pa-
tients) was highly cost-effective compared to No screening
($6.14 per DALY averted, 95% UR: -$20.32 to $36.47) at
current WTP thresholds for Uganda (Table 2). In second-
ary analysis, when including cost of lifetime ART, CRAG
screening cost approximately $557 per DALY averted, still
below the WTP threshold for cost-effectiveness in Uganda.
Secondary analysis
In the base case we assumed all asymptomatic CRAG-
positive patients received preemptive treatment in the
CRAG screening arm, without further evaluation for
subclinical baseline CM. We explored alternative imple-
mentation algorithms for intensified diagnosis and treat-
ment for CRAG-positive patients. If all CRAG-positive
patients received a LP for intensified diagnosis of CM
(with full CM treatment if diagnosed), the ICER for
CRAG screening rose to $32 per DALY averted
Table 2 Costs, Effects, and ICER values of implementing universal CRAG screening




ICER (cost per DALY averted)c
No
screening





10.76 (8.39 to 12.29) 1.52 (−5.46 to 9.42) 8.30
(6.41to 10.79)
25 DALYs averted per
100 participants (13 to 47)
6.14 (−20.32 to 36.47)
Abbreviations: CP current practice, CRAG-LFA cryptococcal antigen lateral flow assay, DALY disability adjusted life-year, ICER incremental cost-effectiveness ratio
aTotal costs represent total health systems costs, inclusive of diagnostic testing and treatment costs related to diagnosed cryptococcal antigenemia and/or
cryptococcal meningitis over a 5 year time period, but excludes lifetime ART costs. DALYs were evaluated over a lifelong time horizon. Future years are discounted
by 3% and ART costs are not included in base case analysis
bThe CRAG-LFA intervention consists of screening all cohort patients for cryptococcal antigenemia with CRAG-LFA, followed by cryptococcal pre-emptive therapy
(CPET) for those who screen positive
cIn secondary analysis, the total costs inclusive of lifetime ART costs were $5772 and $5991 (incremental of139.48) for CP and CRAG-LFA screening arms, respect-
ively. The ICER inclusive of lifetime ART costs was 558 per DALY averted
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compared to No screening. Alternatively, if all CRAG
positive patients were treated for CM (i.e. Amphotericin
followed by fluconazole) irrespective of any additional
evaluation, the ICER rises to $75 per DALY averted
compared to No screening.
In further secondary analysis, we calculated the costs
and effects of CRAG screening at four levels of pro-
grammatic scale-up (25, 50, 75, and 100% of eligible in-
dividuals, Table 3). We found that the incremental costs
and DALYs averted were affected proportionally by per-
centage uptake of CRAG screening, and consequently the
ICER for each level of implementation remained un-
changed at $6.14 per DALY averted. However, the absolute
costs and impact of varied by different levels of population
level coverage of CRAG screening. The total (discounted)
health system cost for an annual estimate of persons with
HIV and CD4 < 100 cells/uL enrolling into care (inclusive
of screening, further diagnostic evaluation when indicated,
and treatment costs) of CRAG screening in Uganda was
estimated at $651,454 at 100% uptake ($473,394,
$303,930, $146,132 for 75%, 50%, 25% uptake respect-
ively). Total mortality among this cohort from CM disease
improved at each level of programmatic implementation
(CM deaths averted compared to ‘no screening’: 307 at
25%, 614 at 50%, 921 at 75%, 1228 at 100% uptake). These
estimates varied based on the estimated number of people
enrolling in HIV care in Uganda as well as the estimated
percentage with CD4 < 100 (Table 3).
Sensitivity analysis
We explored the impact of parameter uncertainty on
our base case cost-effectiveness estimates (at 100% im-
plementation) in one-way and multi-way sensitivity ana-
lyses (see Fig. 2 for selected one-way analyses). We did
not identify any scenarios in which CRAG screening
would not be considered highly cost-effective (i.e. where
ICER dropped below the WTP threshold).
The variables that most impacted the ICER for CRAG
screening included prevalence of cryptococcal antigene-
mia, relative reduction in CM progression among those
who received preemptive therapy, and cost of CRAG-
LFA testing. However, CRAG screening remained highly
cost-effective at current WTP thresholds even at a
CRAG prevalence of 0.5%, CRAG LFA cost of $9.80, and
only 10% efficacy of preemptive treatment. Our model
projected that if the proportion of CRAG positive cohort
patients developing CM over a 5-year time period (des-
pite ART usage) rose above 44%, CRAG screening be-
came cost-saving compared to No screening. CRAG
screening also became cost-saving if preemptive therapy
reduced CM development by 90% compared to no therapy.
In probabilistic sensitivity analysis, CRAG screening
was considered cost-effective compared to ‘no screening’
100% of the time at a WTP threshold of GDP per capita.
CRAG screening was considered cost-saving (both less
expensive and more effective than No screening) in ap-
proximately 32% of simulations.
Discussion
Diagnosis and management of CM remains a significant
clinical and infrastructural problem in Sub-Saharan Africa.
Our study suggests that for HIV-infected patients with
CD4 counts <100 cells/μL, incorporation of routine CRAG
screening using the LFA would be highly cost-effective
compared to no screening. Our model projects that CRAG
screening with preemptive therapy for CRAG-positive indi-
viduals could reduce relative risk of CM mortality among
PLWH with CD4 < 100 by over 40% while increasing costs
by less than $2.00 per patient compared to no screening,
suggesting that CRAG screening represents excellent value
for money for HIV programs in these regions.
Our analysis also provides a unique assessment of alter-
native implementation algorithms for CRAG screening
that have not been previously modeled, including intensi-
fied diagnostic evaluation with LP and providing full em-
piric treatment for CM among all CRAG-positive
individuals. At $32 per DALY averted, incorporation of LP
for all CRAG-positive patients remained well below WTP
thresholds for Uganda and improved outcomes for pa-
tients with sub-clinical CM disease. While treatment of all
CRAG-positive patients with full CM treatment also im-
proved outcomes, it more than doubled the ICER com-
pared to intensified diagnosis ($75 per DALY averted) with
only a marginal mortality benefit. Our results suggest that,
where feasible, intensified diagnostic evaluation of CRAG-
positive patients with LP can improve detection of sub-
clinical CM disease while remaining cost-effective [45].
Sensitivity analysis identified important parameters
underlying the cost-effectiveness of CRAG screening. The
prevalence of CRAG positivity among the cohort popula-
tion had a significant influence on the ICER – as disease
prevalence drops, CRAG screening identifies fewer high-
risk patients and leads to fewer absolute benefits. Despite
this, CRAG screening remained cost effective at the WTP
threshold for Uganda even if prevalence declined to 1%;
this result suggests that CRAG screening need not be lim-
ited to high-prevalence areas. Estimates of CRAG preva-
lence from various cohorts in Thailand and Sub-Saharan
Africa including Ghana, Kenya, Ethiopia, Nigeria, and
South Africa have reported a range of cryptococcal antige-
nemia from 2.2 to 21%, indicating that our results could
be generalizable across much of Sub-Saharan Africa [7,
46]. The US and UK have previously estimated CRAG
prevalences of 2.9 and 5% among cohorts of PLWH with
CD4 < 100, suggesting that routine CRAG screening may
be cost-effective in these populations as well, though fur-
ther evaluation is warranted given the significant differ-
ences in practice and costs [47, 48].
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There are several limitations to our study. Like all
cost-effectiveness analyses, we are limited by the avail-
ability of data to inform estimates for key model param-
eters. When data were limited, we incorporated large
ranges and conducted sensitivity analyses to assess their
impact on cost-effectiveness. Overall, our model projec-
tions are consistent with empirically collected data from
studies evaluating CRAG screening (31–57 deaths per
1000 PLWH) [2, 3, 8]. While base case analysis did not
include ART costs, we performed secondary analysis to
incorporate these costs into each intervention and calcu-
late the ICER inclusive of ART cost. Our model assumes
optimal implementation and uptake of CRAG screening;
however this may not be possible in resource-limited
settings. Additional research is needed to examine infra-
structural and programmatic barriers associated with
implementing a CRAG-LFA screening program.
Our study has significant strengths and differs from pre-
vious analyses in several important ways. First our model
focuses on population-level effects of scaling-up CRAG
screening in a low-income country in Sub-Sarahan Africa,
a region with high cryptococcal burden and approximately
500,000 of the 625,000 yearly CM deaths [1]. Furthermore,
we modeled the incorporation of preemptive therapy for
clinical management of cryptococcal antigenemia and
explored cost-effectiveness at varying degrees of pre-
emptive treatment efficacy. We also incorporated re-
lapse and loss-to-follow-up into our projections and
modeled the intervention at various degrees of scale-
up to estimate realistic implementation efforts. Our
findings build on data from higher income settings
and demonstrate the cost-effectiveness and projected
implementation effects of CRAG-LFA screening for a
high prevalence, low-income region.
Despite WHO recommendations for universal CRAG
screening among eligible patients, implementation is of
paramount importance and remains a challenge in over-
burdened, under-resourced clinics. Despite known
survival benefit with CRAG screening, successful na-
tional implementation will require education of health-
care workers, training of laboratory workers, purchasing
of CRAG LFA kits, and sufficient supply of fluconazole
and ART. In our experience stock-outs of fluconazole
are a common limiting factor. CRAG screening pro-
grams with high rates of loss to follow up, have proven
unsuccessful [45]. Without an advocate in each clinic for
those particularly vulnerable patients with a CD4 < 100
cells/uL, it remains challenging to successfully imple-
ment CRAG screening programs outside of research
studies. Finally, CRAG screening programs need to be
closely linked to ART initiation and retention in care.
ART remains the most important intervention to decrease
mortality in highly immunosuppressed HIV patients.
Notably, we project that a CRAG screening program,
including preemptive treatment, costs approximately
$10.76 per person per year in Uganda. In comparison,
the mean annual price for first line ART is $100 per year
in sub-Saharan Africa, and delivery of ART including lab
monitoring and personnel costs is estimated between
$150 and $500 US dollars per person-year, suggesting
that CRAG screening is relatively inexpensive and could
serve as a key peri-ART intervention for immunosup-
pressed patients [49, 50].
Conclusion
Taken together, our analysis suggests that CRAG screen-
ing would be a highly cost-effective policy intervention in
Uganda, with potential application to much of sub-
Saharan Africa. It also underscores the need for additional
research such as case detection, rates of CM relapse and
loss to follow-up in these regions. Further work should
also focus on potential barriers to implementation and
Fig. 2 Tornado Diagram demonstrating Impact of Model Variables on ICER. Abbreviations: CRAG-LFA –cryptococcal antigen lateral flow assay,
CM – cryptococcal meningitis, CRAG – cryptococcal antigen. Tornado diagram demonstrating the effect of varying six pertinent variables on the ICER
value for CRAG screening compared to CP. The vertical line at $6.14 represents the ICER for the base case analysis
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developing an optimized clinical algorithm for managing
these patients. As access to ART continues to improve in
these regions over time, median CD4 will rise and preva-
lence of CM will likely decrease – developing cost-
effectiveness projections to model this progression will be
useful in guiding allocation of care. As we move towards
universal ART access, implementing CRAG screening has
the potential to reduce the high burden of cryptococcal
disease in Sub-Saharan Africa.
Abbreviations
PLWH: People living with HIV; ART: Antiretroviral therapy; CM: Cryptococcal
meningitis; CRAG: Cryptococcal antigen; DALY: Disability-adjusted life year;
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